Alto Neuroscience (ANRO) Non-Current Debt (2023 - 2026)
Alto Neuroscience (ANRO) posted Non-Current Debt of $13.9 million for Q1 2026, down 14.14% sequentially from $16.2 million in Q4 2025, and down 30.37% YoY from $19.9 million in Q1 2025.
Alto Neuroscience (ANRO) Non-Current Debt (2023 - 2026) Analysis & Trends
Alto Neuroscience has reported Non-Current Debt for 4 years, with the latest figure at $13.9 million in Q1 2026.
- Quarterly Non-Current Debt fell 30.37% year-over-year to $13.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.9 million (down 30.37% YoY) and the FY2025 annual result came in at $16.2 million, up 57.71% from the prior year.
- Non-Current Debt eased to $13.9 million in Q1 2026 per ANRO's latest filing, from $16.2 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $20.3 million in Q3 2025 and troughed at $9.9 million in Q4 2023.
- A 4-year average of $14.1 million and a median of $12.1 million in 2024 frame the typical range for Non-Current Debt.
- The sharpest annual moves came in 2025 and 2026: Non-Current Debt soared 100.22% in 2025, then tumbled 30.37% in 2026.
- Over 4 years, Non-Current Debt stood at $9.9 million in 2023, then increased by 3.99% to $10.3 million in 2024, then surged by 57.71% to $16.2 million in 2025, then decreased by 14.14% to $13.9 million in 2026.
- According to Business Quant data, Non-Current Debt over the past three periods registered $13.9 million, $16.2 million, and $20.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Alto Neuroscience | 1.13 Bn | 1.13 Bn | - | 12.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.42 Mn |
| Mar 31, 2026 | 13.89 Mn |
| Dec 31, 2025 | 16.17 Mn |
| Sep 30, 2025 | 20.31 Mn |
| Jun 30, 2025 | 20.12 Mn |
| Mar 31, 2025 | 19.94 Mn |
| Dec 31, 2024 | 10.25 Mn |
| Sep 30, 2024 | 10.16 Mn |
| Jun 30, 2024 | 10.06 Mn |
| Mar 31, 2024 | 9.96 Mn |
| Dec 31, 2023 | 9.86 Mn |